Reuters logo
BRIEF-FDA accepts Amgen's filing of a supplemental new drug application to add overall survival results to Kyprolis® (carfilzomib) label
August 30, 2017 / 8:12 PM / 3 months ago

BRIEF-FDA accepts Amgen's filing of a supplemental new drug application to add overall survival results to Kyprolis® (carfilzomib) label

Aug 31 (Reuters) - Amgen Inc

* FDA accepts Amgen’s filing of a supplemental new drug application to add overall survival results to Kyprolis® (carfilzomib) label

* Amgen Inc - FDA sets PDUFA target action date of April 30, 2018​

* Amgen Inc - ‍ Adverse events observed in updated analysis were consistent with those previously reported for endeavor​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below